Appendix II — B — Decisions Cited — B
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
B/E Aerospace, Inc. v. C&D Zodiac, Inc., 962 F.3d 1373, 2020 USPQ2d 10706 (Fed. Cir. 2020) 2143
Badger, Ex parte, 1901 C.D. 195, 97 O.G. 1596 (Comm’r Pat. 1901) 608.02(f)
Bager, In re, 47 F.2d 951, 8 USPQ 484 (CCPA 1931) 2121.04
Baird, In re, 16 F.3d 380, 29 USPQ2d 1550 (Fed. Cir. 1994) 2144.05 , 2144.08 , 2163
Baker Hughes, Inc. v. Kirk, 921 F. Supp. 801, 38 USPQ2d 1885 (D.D.C. 1995) 1410.02 , 1412.04
Ball Aerosol v. Ltd. Brands, 555 F.3d 984, 89 USPQ2d 1870 (Fed. Cir. 2009) 2143
Ball Corp., In re, 925 F.2d 1480, 18 USPQ2d 1491 (Fed. Cir. 1991) 2145
Ball Corp. v. United States, 729 F.2d 1429, 221 USPQ 289 (Fed. Cir. 1984) 1412.02 , 1490
Balzarini, Ex parte, 21 USPQ2d 1892 (Bd. Pat. App. & Inter. 1991) 2107.03
Bancorp Services., L.L.C. v. Sun Life Assurance Co. of Canada (U.S.), 687 F.3d 1266, 103 USPQ2d 1425 (Fed. Cir. 2012) 2106.04(a)(1) , 2106.05(d) , 2106.05(g)
Bandel, In re, 348 F.2d 563, 146 USPQ 389 (CCPA 1965) 715
Baran v. Medical Device Techs., Inc., 616 F.3d 1309, 96 USPQ2d 1057 (Fed. Cir. 2010) 2181
Barber, Ex parte, 187 USPQ 244 (Bd. App. 1974) 2173.05(j)
Barber, In re, 81 F.2d 231, 28 USPQ 187 (CCPA 1936) 804
Barker, In re, 559 F.2d 588, 194 USPQ 470 (CCPA 1977) 2161 , 2163
Barmag Barmer Maschinenfabrik AG v. Murata Mach., Ltd., 731 F.2d 831, 221 USPQ 561 (Fed. Cir. 1984) 2133.03(b)
Barr, In re, 444 F.2d 588, 170 USPQ 330 (CCPA 1971) 2173.05(a) , 2173.05(g) , 2173.05(i)
Bartfeld, Ex parte, 16 USPQ2d 1714 (Bd. Pat. App. & Inter. 1990) 2136.01
Bartfeld, In re, 925 F.2d 1450, 17 USPQ2d 1885 (Fed. Cir. 1991) 804 , 804.03 , 2136.01 , 2136.05 , 2136.05(a) , 2139.03 , 2141.01 , 2152.07
Basell Poliolefine, In re, 547 F.3d 1371, 89 USPQ2d 1030 (Fed. Cir. 2008) 804
Basmadjian v. Landry, 54 USPQ2d 1617 (Bd. Pat. App. & Inter. 1997) 2305
Bass, In re, 314 F.3d 575, 65 USPQ2d 1156 (Fed. Cir. 2002) 2258.01
Bass, In re, 474 F.2d 1276, 177 USPQ 178 (CCPA 1973) 2004 , 2138 , 2138.03
Bauman, In re, 683 F.2d 405, 214 USPQ 585 (CCPA 1982) 1451
BASCOM Global Internet v. AT&T Mobility, LLC, 827 F.3d 1341, 119 USPQ2d 1236 (Fed. Cir. 2016) 2106.04 , 2106.04(a)(1) , 2106.04(d)(1) , 2106.05 , 2106.05(a) , 2106.05(d) , 2106.05(e) , 2106.05(f) , 2106.06(b)
Bausch & Lomb v. Barnes-Hind/Hydrocurve, Inc., 796 F.2d 443, 230 USPQ 416 (Fed. Cir. 1986) 2141.02
Baxalta Inc. v Genentech, Inc., 81 F.4th 1362, 2023 USPQ2d 1103 (Fed. Cir. 2023) 2164.01
Baxter Diagnostics v. AVL Scientific Corp., 798 F. Supp. 612, 25 USPQ2d 1428 (C.D., Cal. 1992) 2751
Baxter, In re, 656 F.2d 679, 210 USPQ 795 (CCPA 1981) 2111.03
Baxter International Inc., In re, 678 F.3d 1357, 102 USPQ2d 1925 (Fed. Cir. 2012) 2242 , 2286
Baxter Travenol Labs., In re, 952 F.2d 388, 21 USPQ2d 1281 (Fed. Cir. 1991) 2131.01 , 2145
Bayer AG and Bayer Corporation v. Carlsbad Technology Inc., 298 F.3d 1377, 64 USPQ2d 1045 (Fed. Cir. 2002) 2701
Bayer AG v. Housey Pharm., Inc., 340 F.3d 1367, 68 USPQ2d 1001 (Fed. Cir. 2003) 2106.04(a)(1)
Bayer, In re, 568 F.2d 1357, 196 USPQ 670 (CCPA 1978) 2128.01 , 2152.02(e)
Bayer Schering Pharma A.G. v. Barr Labs., Inc., 575 F.3d 1341, 91 USPQ2d 1569 (Fed. Cir. 2009) 2143
Bayles, Ex parte, 176 O.G. 750 (Comm’r Pat. 1912) 1460
B. Braun Medical, Inc. v. Abbott Labs., 124 F.3d 1419, 43 USPQ2d 1896 (Fed. Cir. 1997) 2163 , 2181 , 2182
Beattie, In re, 974 F.2d 1309, 24 USPQ2d 1040 (Fed. Cir. 1992) 716.01(c) , 2145
Beck, In re, 155 F.2d 398, 69 USPQ 520 (CCPA 1946) 715.01(b)
Becket, In re, 88 F.2d 684, 33 USPQ 33 (CCPA 1937) 2144.05
Beckman Instruments v. LKB Produkter AB, 892 F.2d 1547, 13 USPQ2d 1301 (Fed. Cir. 1989) 2121.01 , 2158
Becton, Dickinson & Co. v. Baxter Corp. Englewood, 998 F.3d 1337, 2021 USPQ2d 586 (Fed. Cir. 2021) 2136
Beech Aircraft Corp. v. EDO Corp., 990 F.2d 1237, 26 USPQ2d 1572 (Fed. Cir. 1993) 301 , 2109
Beik, Ex parte, 161 USPQ 795 (Bd. App. 1968) 2135.01
Beineke, In re, 690 F.3d 1344, 103 USPQ2d 1872 (Fed. Cir. 2012) 1601
Belcher Pharms., LLC v. Hospira, Inc., 11 F.4th 1345, 2021 USPQ2d 909 (Fed. Cir. 2021) 2001.06(e) , 2004
Belkin Int'l, Inc. v. Kappos, 696 F.3d 1379, 104 USPQ2d 1348 (Fed. Cir. 2012) 2248
Bell Communications Research, Inc. v. Vitalink Communications Corp., 55 F.3d 615, 34 USPQ2d 1816 (Fed. Cir. 1995) 2111.02 , 2163
Bell, In re, 991 F.2d 781, 26 USPQ2d 1529 (Fed. Cir. 1993) 2144.08 , 2144.09 , 2163
B.E. Meyers & Co. v. United States, 56 USPQ2d 1110 (Fed. Cl. 2000) 1412.01
Benger Labs. Ltd. v. R.K. Laros Co., 209 F. Supp. 639, 135 USPQ 11 (E.D. Pa. 1962) 2165
Benke, Ex parte, 1904 C.D. 63, 108 O.G. 1588 (Comm’r Pat. 1904) 811.02
Bennage v. Phillippi, 1876 C.D. 135, 9 O.G. 1159 (Comm’r Pat. 1876) 1504.01(d)
Bennett, In re, 766 F.2d 524, 226 USPQ 413 (Fed. Cir. 1985) 1403 , 1412.03
Benno, In re, 768 F.2d 1340, 226 USPQ 683 (Fed. Cir. 1985) 2163 , 2163.06
Berg, In re, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998) 804 , 1451
Berg, In re, 320 F.3d 1310, 65 USPQ2d 2003 (Fed. Cir. 2003) 2141
Bergel, In re, 292 F.2d 955, 130 USPQ 206 (1961) 2141
Bergen, In re, 120 F.2d 329, 49 USPQ 749 (CCPA 1941) 2144.05
Berger, In re, 279 F.3d 975, 61 USPQ2d 1523 (Fed. Cir. 2002) 2304.02(c)
Bergstrom, In re, 427 F.2d 1394, 166 USPQ 256 (CCPA 1970) 2144.04
Berkman, In re, 642 F.2d 427, 209 USPQ 45 (CCPA 1981) 1504.04 , 1504.20
Berman v. Housey, 291 F.3d 1345, 63 USPQ2d 1023 (Fed. Cir. 2002) 2303
Bernhardt, L.L.C. v. Collezione Europa USA, Inc., 386 F.3d 1371, 72 USPQ2d 1901 (Fed. Cir. 2004) 2133.03(a)
Bernhart, In re, 417 F.2d 1395, 163 USPQ 611 (CCPA 1969) 2173.05(j)
Berry Sterling Corp. v. Pescor Plastics Inc., 122 F.3d 1452, 43 USPQ2d 1953 (Fed. Cir. 1997) 1504.01(c)
Bertsch, In re, 132 F.2d 1014, 56 USPQ 379 (CCPA 1942) 2111.03
Best, In re, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) 2112 , 2112.01 , 2112.02 , 2114
Bettcher Industries, Inc. v. Bunzl USA, Inc., 661 F.3d 629, 100 USPQ2d 1433 (Fed. Cir. 2011) 2114
Bey v. Kollonitsch, 806 F.2d 1024, 231 USPQ 967 (Fed. Cir. 1986) 2138.06
BIC Leisure Prods., Inc., v. Windsurfing Int’l, Inc., 1 F.3d 1214, 27 USPQ2d 1671 (Fed. Cir. 1993) 1460
Biesecker, Ex parte, 144 USPQ 129 (Bd. App. 1964) 715.02 , 715.03
Bigham v. Godtfredsen, 857 F.2d 1415, 8 USPQ2d 1266 (Fed. Cir. 1988) 2138.01 , 2138.05
Bigio, In re, 381 F.3d 1320, 72 USPQ2d 1209 (Fed. Cir. 2004) 2141.01(a) , 2173.01
Billottet, Ex parte, 192 USPQ 413 (Bd. App. 1976) 2137
Bilski, In re, 545 F.3d 943, 88 USPQ2d 1385 (Fed. Cir. 2008) 2106
Bilski v. Kappos, 561 U.S. 593, 95 USPQ2d 1001 (2010) 2104 , 2106 , 2106.04 , 2106.04(a) , 2106.04(a)(1) , 2106.04(a)(2) , 2106.05 , 2106.05(b) , 2106.05(c) , 2106.05(e) , 2106.05(g) , 2106.05(h)
Bindra v. Kelly, 206 USPQ 570 (Bd. Pat. Inter. 1979) 2138.05
Biogen Int’l GmbH v. Banner Life Scis. LLC, 956 F.3d 1351, 2020 USPQ2d 10385 (Fed. Cir. 2020) 2750 , 2751
Biogen MA Inc. v. EMD Serono, Inc., 976 F.3d 1326, 2020 USPQ2d 11129 (Fed. Cir. 2020) 2113
Biomedino, LLC v. Waters Technologies Corp., 490 F.3d 946, 83 USPQ2d 1118 (Fed. Cir. 2007) 2163 , 2181
Bird Provision Co. v. Owens Country Sausage, Inc., 568 F.2d 369, 197 USPQ 134 (5th Cir. 1978) 2133.03(a)
Birmingham v. Randall, 171 F.2d 957, 80 USPQ 371 (CCPA 1948) 2138.05
Blackboard, Inc. v. Desire2Learn, Inc., 574 F.3d 1371, 91 USPQ2d 1481 (Fed. Cir. 2009) 2181
Black & Decker, Inc. v. Pittway Corp., 636 F.2d 1193, 231 USPQ 252 (N.D. Ill. 1986) 1504.02
Blacklight Power, Inc. v. Rogan, 295 F.3d 1269, 63 USPQ2d 1534 (Fed. Cir. 2002) 1134 , 1308
Blaisdell, In re, 242 F.2d 779, 113 USPQ 289 (CCPA 1957) 2133.03(a) , 2133.03(b) , 2133.03(e)(3) , 2133.03(e)(5)
Blake, In re, 358 F.2d 750, 149 USPQ 217 (CCPA 1966) 715.07
Blanc, Ex parte, 13 USPQ2d 1383 (Bd. Pat. App. & Inter. 1989) 716.02(c) , 2143.02
Bland, Ex parte, 3 USPQ2d 1103 (Bd. Pat App. & Inter. 1986) 2141.01(a)
Blattner, Ex parte, 2 USPQ2d 2047 (Bd. Pat. App. & Inter. 1987) 2144.09
Blisscraft of Hollywood v. United Plastic Co., 189 F. Supp 333, 127 USPQ 452 (S.D.N.Y. 1960) 1504.01(c)
Blondel, In re, 499 F.2d 1311, 182 USPQ 294 (CCPA 1974) 716.02(b)
Blonder-Tongue Labs., Inc. v. Univ. of Ill., Foundation, 402 U.S. 313, 169 USPQ 513 (1971) 2012.01
Blout, In re, 333 F.2d 928, 142 USPQ 173 (CCPA 1964) 715
Blum, In re, 374 F.2d 904, 153 USPQ 177 (CCPA 1967) 1503.01 , 1503.02
Blumcraft of Pittsburgh v. Ladd, 238 F. Supp. 648, 144 USPQ 562 (D.D.C. 1965) 1504.05 , 1504.06
Board of Education ex rel. Board of Trustees of Florida State Univ. v. American Bioscience Inc., 333 F.3d 1330, 67 USPQ2d 1252 (Fed. Cir. 2003) 2109
Boehringer Ingelheim Int’l v. Barr Laboratories, 592 F.3d 1340, 93 USPQ2d 1417 (Fed. Cir. 2010) 804.02 , 1490 , 2762.01
Boeing Co. v. Comm’r. of Patents & Trademarks, 853 F.2d 878, 7 USPQ2d 1487 (Fed. Cir. 1988) 2279
Boesch, In re, 617 F.2d 272, 205 USPQ 215 (CCPA 1980) 716.02(b)
Bogese, In re, 303 F.3d 1362, 64 USPQ2d 1448 (Fed. Cir. 2002) 2190
Bogoslowsky v. Huse, 142 F.2d 75, 61 USPQ 349 (CCPA 1944) 2138.03
Bolkcom v. Carborundum Co., 523 F.2d 492, 187 USPQ 466 (6th Cir. 1975) 2003
Bond, In re, 910 F.2d 831, 15 USPQ2d 1566 (Fed. Cir. 1990) 2131 , 2152.02(b) , 2183 , 2184
Bondiou, Ex parte, 132 USPQ 356 (Bd. App. 1961) 2163.07
Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 9 USPQ2d 1847 (1989) 2133.02
Boon, In re, 439 F.2d 724, 169 USPQ 231 (CCPA 1971) 1204.04
Borden, In re, 90 F.3d 1570, 39 USPQ2d 1524 (Fed. Cir. 1996) 1504.03
Borkowski, In re, 422 F.2d 904, 164 USPQ 642 (CCPA 1970) 707.07(l) , 2164.02 , 2174
Borkowski, In re, 505 F.2d 713, 184 USPQ 29 (CCPA 1974) 715.07
Bose Corp. v. JBL, Inc., 274 F.3d 1354, 61 USPQ2d 1216 (Fed. Cir. 2001) 2173.05 , 2173.05(e)
Bosies v. Benedict, 27 F.3d 539, 30 USPQ2d 1862 (Fed. Cir. 1994) 2138.04
Bostwick, In re, 102 F.2d 886, 41 USPQ 279 (CCPA 1939) 1449.02
Bosy, In re, 360 F.2d 972, 149 USPQ 789 (CCPA 1966) 2165.01
Bowen, In re, 492 F.2d 859, 181 USPQ 48 (CCPA 1974) 2164.04
Bowers, In re, 359 F.2d 886, 149 USPQ 570 (CCPA 1966) 2146.02
Bowser Inc. v. United States, 388 F.2d 346, 156 USPQ 406 (Ct. Cl. 1967) 2141
Bowyer, Ex parte, 42 USPQ 526, 1939 C.D. 5, 505 O.G. 759 (Comm’r Pat. 1939) 715.07(b)
Bozek, In re, 416 F.2d 1385, 163 USPQ 545(CCPA 1969)) 2143
Braat, In re, 937 F.2d 589, 19 USPQ2d 1289 (Fed. Cir. 1991) 804 , 1504.06
Brader v. Schaeffer, 193 USPQ 627 (Bd. Pat. Inter. 1976) 2109
Braithwaite, In re, 379 F.2d 594, 154 USPQ 29 (CCPA 1967) 804 , 804.02 , 806.04(i)
Brana, In re, 51 F.3d 1560, 34 USPQ2d 1436 (Fed. Cir. 1995) 2107.01 , 2107.03 , 2164.01(c) , 2107.02 , 2164.02 , 2164.04 , 2164.07
Brandstadter, In re, 484 F.2d 1395, 179 USPQ 286 (CCPA 1973) 716.01(c) , 716.09 , 2164.05 , 2164.06(c)
Brandt, In re, 886 F.3d 1171, 126 USPQ2d 1079 (Fed. Cir. 2018) 2144.05
Brasseler, U.S.A. I, L.P. v. Stryker Sales Corp., 267 F.3d 1370, 60 USPQ2d 1482 (Fed. Cir. 2001) 2001.06
Brenner v. Manson, 383 U.S. 519, 148 USPQ 689 (1966) 2103 , 2107.01 , 2107.02
Brenner v. State of Israel, 400 F.2d 789, 158 USPQ 584 (D.C. Cir. 1968) 216.01 , 1402 , 1417 , 1444
Breslow, In re, 616 F.2d 516, 205 USPQ 221 (CCPA 1980) 2164.01(b)
Brian, Ex parte, 118 USPQ 242 (Bd. App. 1958) 2173.05(t)
Bridgeford, In re, 357 F.2d 679, 149 USPQ 55 (CCPA 1966) 806.05(f)
Bristol-Myers Squibb Co. v. Kappos, 891 F.Supp.2d 135 (D.D.C. 2012) 2734
Bristol-Myers Squibb Co. v. Pharmachemie BV, 361 F.3d 1343, 70 USPQ2d 1097 (Fed. Cir. 2004) 804.01 , 819
Bristol-Myers Squibb Co. v. Rhone Poulenc Rorer, Inc., 326 F.3d 1226, 66 USPQ2d 1481 (Fed. Cir. 2003) 2001.04
Brookhill-Wilk 1, LLC v. Intuitive Surgical, Inc., 334 F.3d 1294, 67 USPQ2d 1132 (Fed. Cir. 2003) 2111.01
Brooktree Corp. v. Advanced Micro Devices, Inc., 977 F.2d 1555, 24 USPQ2d 1401 (Fed. Cir. 1992) 2107.01
Broos v. Barton, 142 F.2d 690, 61 USPQ 447 (CCPA 1944) 2138.06
Brouwer, In re, 77 F.3d 422, 37 USPQ2d 1663 (Fed. Cir. 1996) 2116.01 , 2144.08 , 2147 , 2158
Brower, In re, 433 F.2d 813, 167 USPQ 684 (CCPA 1970) 2172
Brown, In re, 459 F.2d 531, 173 USPQ 685 (CCPA 1972) 2113 , 2183
Brown, In re, 477 F.2d 946, 177 USPQ 691 (CCPA 1973) 2161.01 , 2164.06(c)
Brown, In re, 645 Fed. App'x. 1014 (Fed. Cir. 2016) 2106.04(a)(1) , 2106.05(f) , 2106.05(g)
Brown v. 3M, 265 F.3d 1349, 60 USPQ2d 1375 (Fed. Cir. 2001) 2131
Bruckelmyer v. Ground Heaters, Inc., 445 F. 3d 1374, 78 USPQ2d 1684 (Fed. Cir. 2006) 2127 , 2152.02(e)
Brummer, Ex parte, 12 USPQ2d 1653 (Bd. Pat. App. & Inter. 1989) 2173.05(b)
Bryan, In re, 323 Fed. App'x. 898 (Fed. Cir. 2009) 2111.05 , 2112.01
BSG Tech. LLC v. Buyseasons, Inc., 899 F.3d 1281, 127 USPQ2d 1688 (Fed. Cir. 2018) 2106.04(a)(2)
Buchner, In re, 929 F.2d 660, 18 USPQ2d 1331 (Fed. Cir. 1991) 716.09 , 2107.02 , 2164.01 , 2164.05 , 2164.05(a) , 2164.08
Budde v. Harley-Davidson, Inc., 250 F.3d 1369, 58 USPQ2d 1801 (Fed. Cir. 2001) 2181 , 2182
Budnick, In re, 537 F.2d 535, 190 USPQ 422 (CCPA 1976) 2164.05(a) , 2164.06(c)
Buildex v. Kason Indus., Inc., 849 F.2d 1461, 7 USPQ2d 1325 (Fed. Cir. 1988) 2133.03(b)
Bundy, In re, 642 F.2d 430, 209 USPQ 48 (CCPA 1981) 2107.02 , 2164.04 , 2164.06(b) , 2164.07 , 2165.04
Burckel, In re, 592 F.2d 1175, 201 USPQ 67 (CCPA 1979) 716.02(e)
Burhans, In re, 154 F.2d 690, 69 USPQ 330 (CCPA 1946) 2144.04
Burlington Industries Inc. v. Quigg, 822 F.2d 1581, 3 USPQ2d 1436 (Fed. Cir. 1987) 716.05 , 2173.02
Burroughs Wellcome Co. v. Barr Lab., Inc., 40 F.3d 1223, 32 USPQ2d 1915 (Fed. Cir. 1994) 2138.04 , 2163
Burr v. Duryee, 68 U.S. 531, 17 L. Ed. 650 (1863) 2106.03
Burrowes, Ex parte, 110 O.G. 599, 1904 C.D. 155 (Comm’r Pat. 1904) 1214.01
Bush, In re, 296 F.2d 491, 131 USPQ 263 (CCPA 1961) 1207.03(a)
Busse, Ex parte, 1 USPQ2d 1908 (Bd. Pat. App. & Inter. 1986) 2107.03
Buszard, In re, 504 F.3d 1364, 84 USPQ2d 1749 (Fed. Cir. 2007) 2111 , 2173.01 , 2173.02
Buting, In re, 418 F.2d 540, 163 USPQ 689 (CCPA 1969) 2107.03
buySAFE, Inc. v. Google, Inc., 765 F.3d 1350, 112 USPQ2d 1093 (Fed. Cir. 2014) 2106.04(a)(1) , 2106.05(d) , 2106.05(h)
Cited authority
- 2143 Examples of Basic Requirements of a Prima Facie Case of Obviousness
- 608.02(f) Modifications in Drawings
- 2121.04 Apparatus and Articles — What Constitutes Enabling Prior Art
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 1410.02 Assignee Consent to the Reissue
- 1412.04 Correction of Inventorship By Reissue
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 1412.02 Recapture of Canceled Subject Matter
- 1490 Disclaimers
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 2106.04(a)(2) Abstract Idea Groupings
- 2106.05(d) Well-Understood, Routine, Conventional Activity
- 2106.05(g) Insignificant Extra-Solution Activity
- 715 Swearing Behind a Reference — Affidavit or Declaration Under 37 CFR 1.131(a)
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 2173.05(j) Old Combination
- 804 Definition of Double Patenting
- 2161 Three Separate Requirements for Specification Under 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2133.03(b) “On Sale”
- 2173.05(a) New Terminology
- 2173.05(g) Functional Limitations
- 2173.05(i) Negative Limitations
- 2136.01 Status of Unpublished or Published as Redacted U.S. Application as a Reference Under Pre-AIA 35 U.S.C. 102(e)
- 804.03 Commonly Owned Inventions of Different Inventive Entities; Non-Commonly Owned Inventions Subject to a Joint Research Agreement
- 2136.05 Overcoming a Rejection Under Pre-AIA 35 U.S.C. 102(e)
- 2136.05(a) Antedating a Pre-AIA 35 U.S.C. 102(e) Reference
- 2139.03 Form Paragraphs for Use in Rejections Under Pre-AIA 35 U.S.C. 102
- 2141.01 Scope and Content of the Prior Art
- 2152.07 Form Paragraphs for Use in Rejections Under AIA 35 U.S.C. 102
- 2305 Requiring a Priority Showing
- 2258.01 Use of Previously Cited/Considered Art in Rejections
- 2004 Aids to Compliance With Duty of Disclosure
- 2138 Pre-AIA 35 U.S.C. 102(g)
- 2138.03 “By Another Who Has Not Abandoned, Suppressed, or Concealed It”
- 1451 Divisional Reissue Applications; Continuation Reissue Applications Where the Parent is Pending
- 2106.04 Eligibility Step 2A: Whether a Claim is Directed to a Judicial Exception
- 2106.04(d)(1) Evaluating Improvements in the Functioning of a Computer, or an Improvement to Any Other Technology or Technical Field in Step 2A Prong Two
- 2106.05 Eligibility Step 2B: Whether a Claim Amounts to Significantly More
- 2106.05(a) Improvements to the Functioning of a Computer or To Any Other Technology or Technical Field
- 2106.05(e) Other Meaningful Limitations
- 2106.05(f) Mere Instructions To Apply An Exception
- 2106.06(b) Clear Improvement to a Technology or to Computer Functionality
- 2141.02 Differences Between Prior Art and Claimed Invention
- 2164.01 Test of Enablement
- 2751 Eligibility Requirements
- 2111.03 Transitional Phrases
- 2242 Criteria for Deciding Request Filed under 35 U.S.C. 302
- 2286 Ex Parte Reexamination and Litigation Proceedings
- 2131.01 Multiple Reference 35 U.S.C. 102 Rejections
- 2701 Patent Term
- 2128.01 Level of Public Accessibility Required
- 2152.02(e) Otherwise Available to the Public
- 1460 Effect of Reissue
- 2182 Search and Identification of the Prior Art
- 716.01(c) Probative Value of Objective Evidence
- 715.01(b) Reference and Application Have Common Assignee
- 2121.01 Use of Prior Art in Rejections Where Operability is in Question
- 2158 AIA 35 U.S.C. 103
- 2136 Pre-AIA 35 U.S.C. 102(e)
- 301 Ownership/Assignability of Patents and Applications
- 2109 Inventorship
- 2135.01 The Four Requirements of Pre-AIA 35 U.S.C. 102(d)
- 1601 Introduction: The Act, Scope, Type of Plants Covered
- 2001.06(e) Information Relating to Regulatory Review
- 2248 Petition From Denial of Request Filed Under 35 U.S.C. 302
- 2111.02 Effect of Preamble
- 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)
- 1412.01 Reissue Claims Must Be for Same General Invention
- 2165 The Best Mode Requirement
- 811.02 New Requirement After Compliance With Preceding Requirement
- 1504.01(d) Simulation
- 1403 Diligence in Filing
- 1412.03 Broadening Reissue Claims
- 2163.06 Relationship of Written Description Requirement to New Matter
- 2141 Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103
- 2304.02(c) Explaining Priority
- 2144.04 Legal Precedent as Source of Supporting Rationale
- 1504.04 Considerations Under 35 U.S.C. 112
- 1504.20 Benefit Under 35 U.S.C. 120
- 2303 Completion of Examination
- 2133.03(a) “Public Use”
- 1504.01(c) Lack of Ornamentality
- 2112 Requirements of Rejection Based on Inherency; Burden of Proof
- 2112.01 Composition, Product, and Apparatus Claims
- 2112.02 Process Claims
- 2114 Apparatus and Article Claims — Functional Language
- 2138.06 “Reasonable Diligence”
- 715.02 How Much of the Claimed Invention Must Be Shown, Including the General Rule as to Generic Claims
- 715.03 Genus-Species, Practice Relative to Cases Where Predictability Is in Question
- 2138.01 Interference Practice
- 2138.05 “Reduction to Practice”
- 2141.01(a) Analogous and Nonanalogous Art
- 2173.01 Interpreting the Claims
- 2137 Pre-AIA 35 U.S.C. 102(f)
- 2106 Patent Subject Matter Eligibility
- 2104 Requirements of 35 U.S.C. 101
- 2106.04(a) Abstract Ideas
- 2106.05(b) Particular Machine
- 2106.05(c) Particular Transformation
- 2106.05(h) Field of Use and Technological Environment
- 2750 Patent Term Extension for Delays at other Agencies under 35 U.S.C. 156
- 2113 Product-by-Process Claims
- 1504.02 Novelty
- 1134 Third Party Inquiries and Correspondence in a Published Application
- 1308 Withdrawal From Issue
- 2133.03(e)(3) “Completeness” of the Invention
- 2133.03(e)(5) Experimentation and Degree of Supervision and Control
- 715.07 Facts and Documentary Evidence
- 716.02(c) Weighing Evidence of Expected and Unexpected Results
- 2143.02 Reasonable Expectation of Success Is Required
- 716.02(b) Burden on Applicant
- 2012.01 Collateral Estoppel
- 1503.01 Specification
- 1503.02 Drawing
- 1504.05 Restriction
- 1504.06 Double Patenting
- 804.02 Avoiding a Double Patenting Rejection
- 2762.01 Duty of Disclosure When a Terminal Disclaimer is Filed During Patent Term Extension Proceedings
- 2279 Appeal to Courts
- 2190 Prosecution Laches and Res Judicata
- 2003 Disclosure __ When Made
- 2131 Anticipation — Application of 35 U.S.C. 102
- 2152.02(b) Described in a Printed Publication
- 2183 Making a Prima Facie Case of Equivalence
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made
- 2163.07 Amendments to Application Which Are Supported in the Original Description
- 2133.02 Rejections Based on Publications and Patents
- 1204.04 Official Record on Appeal
- 1504.03 Nonobviousness
- 707.07(l) Comment on Examples
- 2164.02 Working and Prophetic Examples
- 2174 Relationship Between the Requirements of 35 U.S.C. 112(a) and (b) or Pre-AIA 35 U.S.C. 112, First and Second Paragraphs
- 2173.05 Specific Topics Related to Issues Under 35 U.S.C. 112(b) or Pre-AIA 35 U.S.C. 112, Second Paragraph
- 2173.05(e) Lack of Antecedent Basis
- 2138.04 “Conception”
- 1449.02 Interference in Reissue
- 2165.01 Considerations Relevant to Best Mode
- 2164.04 Burden on the Examiner Under the Enablement Requirement
- 2146.02 Establishing Common Ownership or Joint Research Agreement Under Pre-AIA 35 U.S.C. 103(c)
- 715.07(b) Interference Testimony Sometimes Used
- 806.04(i) Generic Claims Presented In a Separate Application After Issuance of Species Claims
- 2107.01 General Principles Governing Utility Rejections
- 2164.01(c) How to Use the Claimed Invention
- 2107.02 Procedural Considerations Related to Rejections for Lack of Utility
- 2164.07 Relationship of Enablement Requirement to Utility Requirement of 35 U.S.C. 101
- 716.09 Sufficiency of Disclosure
- 2164.05 Determination of Enablement Based on Evidence as a Whole
- 2164.06(c) Examples of Enablement Issues – Computer Programming Cases
- 2001.06 Sources of Information under 37 CFR 1.56
- 2103 Patent Examination Process
- 216.01 Perfecting Claim for Priority Under 35 U.S.C. 119(a)-(d) or (f) After Issuance of a Patent
- 1402 Grounds for Filing
- 1417 Claim for Priority Under 35 U.S.C. 119(a)-(d)
- 1444 Review of Reissue Oath/Declaration
- 2164.01(b) How to Make the Claimed Invention
- 2173.05(t) Chemical Formula
- 806.05(f) Process of Making and Product Made
- 2734 Application for Patent Term Adjustment; Due Care Showing
- 804.01 Prohibition of Nonstatutory Double Patenting Rejections Under 35 U.S.C. 121
- 819 Office Generally Does Not Permit Shift
- 2001.04 Information Under 37 CFR 1.56(a)
- 2111.01 Plain Meaning
- 2116.01 Novel, Nonobvious Starting Material or End Product
- 2147 Biotechnology Process Applications; Pre-AIA 35 U.S.C. 103(b)
- 2172 Subject Matter Which the Inventor or a Joint Inventor Regards as The Invention
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2127 Domestic and Foreign Patent Applications as Prior Art
- 2173.05(b) Relative Terminology
- 2111.05 Functional and Nonfunctional Descriptive Material
- 2164.05(a) Specification Must Be Enabling as of the Filing Date
- 2164.08 Enablement Commensurate in Scope With the Claims
- 2164.06(b) Examples of Enablement Issues — Biological and Chemical Cases
- 2165.04 Examples of Evidence of Concealment
- 716.02(e) Comparison With Closest Prior Art
- 716.05 Skepticism of Experts
- 2173.02 Determining Whether Claim Language is Definite
- 2106.03 Eligibility Step 1: The Four Categories of Statutory Subject Matter
- 1214.01 Procedure Following New Ground of Rejection by Board
- 1207.03(a) Determining Whether a Ground of Rejection is New
- 2111 Claim Interpretation; Broadest Reasonable Interpretation